| pubmed-article:2681933 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2681933 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:2681933 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:2681933 | lifeskim:mentions | umls-concept:C0205191 | lld:lifeskim |
| pubmed-article:2681933 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:2681933 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:2681933 | pubmed:dateCreated | 1989-12-21 | lld:pubmed |
| pubmed-article:2681933 | pubmed:abstractText | The production and targeting of a major T cell derived lymphokine, Interleukin 2 (IL-2), were studied in 23 uremic patients undergoing regular hemodialysis treatment and 20 uremic patients prior to the onset of renal replacement therapy. In hemodialyzed patients, abnormally increased proportions of circulating T cells spontaneously expressing high affinity IL-2 receptors (IL-2 Rec) were detected: they bound a monoclonal antibody specifically directed to the IL-2 Rec 55 kDa chain (Tac antigen) (mean +/- SEM: 7.12 +/- 0.81% in patients vs. 2.15 +/- 0.39% in normal controls, P less than 0.0001) and significantly proliferated in presence of human recombinant IL-2 alone (mean +/- SEM: 5438 +/- 729 cpm in patients vs. 1647 +/- 244 cpm in normal controls). Hemodialyzed patients also exhibited significantly increased serum levels of soluble IL-2 receptor (mean +/- SEM: 4036 +/- 947 U/ml in patients vs. 253 +/- 29 U/ml in normal controls. P less than 0.001). Moreover, a significantly decreased IL-2 activity was detected in the supernatants of stimulated T cells from hemodialyzed patients (mean +/- SEM: 0.93 +/- 0.12 U/ml in patients vs. 2.49 +/- 0.22 U/ml in normal controls, P less than 0.0001). In nine hemodialyzed patients who were analyzed before and immediately after the hemodialysis session no acute modifications of the various parameters analyzed were detected. Although less profound, a similar pattern of T cell abnormalities was observed in the uremic non-hemodialyzed patients studied.(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:2681933 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2681933 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2681933 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2681933 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2681933 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2681933 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2681933 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:2681933 | pubmed:issn | 0085-2538 | lld:pubmed |
| pubmed-article:2681933 | pubmed:author | pubmed-author:NelsonD LDL | lld:pubmed |
| pubmed-article:2681933 | pubmed:author | pubmed-author:CAMPH MHM | lld:pubmed |
| pubmed-article:2681933 | pubmed:author | pubmed-author:NaretCC | lld:pubmed |
| pubmed-article:2681933 | pubmed:author | pubmed-author:DruekeTT | lld:pubmed |
| pubmed-article:2681933 | pubmed:author | pubmed-author:BeaurainGG | lld:pubmed |
| pubmed-article:2681933 | pubmed:author | pubmed-author:ChatenoudLL | lld:pubmed |
| pubmed-article:2681933 | pubmed:author | pubmed-author:UrenaPP | lld:pubmed |
| pubmed-article:2681933 | pubmed:author | pubmed-author:MarconLL | lld:pubmed |
| pubmed-article:2681933 | pubmed:author | pubmed-author:GrateauGG | lld:pubmed |
| pubmed-article:2681933 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2681933 | pubmed:volume | 36 | lld:pubmed |
| pubmed-article:2681933 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2681933 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2681933 | pubmed:pagination | 636-44 | lld:pubmed |
| pubmed-article:2681933 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:2681933 | pubmed:meshHeading | pubmed-meshheading:2681933-... | lld:pubmed |
| pubmed-article:2681933 | pubmed:meshHeading | pubmed-meshheading:2681933-... | lld:pubmed |
| pubmed-article:2681933 | pubmed:meshHeading | pubmed-meshheading:2681933-... | lld:pubmed |
| pubmed-article:2681933 | pubmed:meshHeading | pubmed-meshheading:2681933-... | lld:pubmed |
| pubmed-article:2681933 | pubmed:meshHeading | pubmed-meshheading:2681933-... | lld:pubmed |
| pubmed-article:2681933 | pubmed:meshHeading | pubmed-meshheading:2681933-... | lld:pubmed |
| pubmed-article:2681933 | pubmed:meshHeading | pubmed-meshheading:2681933-... | lld:pubmed |
| pubmed-article:2681933 | pubmed:meshHeading | pubmed-meshheading:2681933-... | lld:pubmed |
| pubmed-article:2681933 | pubmed:meshHeading | pubmed-meshheading:2681933-... | lld:pubmed |
| pubmed-article:2681933 | pubmed:meshHeading | pubmed-meshheading:2681933-... | lld:pubmed |
| pubmed-article:2681933 | pubmed:meshHeading | pubmed-meshheading:2681933-... | lld:pubmed |
| pubmed-article:2681933 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2681933 | pubmed:articleTitle | In vivo T cell preactivation in chronic uremic hemodialyzed and non-hemodialyzed patients. | lld:pubmed |
| pubmed-article:2681933 | pubmed:affiliation | Inserm U 25, CNRS UA 122, Ass. Cl. Bernard Hôpital Necker, Paris, France. | lld:pubmed |
| pubmed-article:2681933 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2681933 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2681933 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2681933 | lld:pubmed |
